The 2016 multiple-sclerosis therapy-area 'Corporate Reputation' results are from 54 patient groups specialising in multiple sclerosis, and based in 22 countries. These results are derived from the global element of the survey (conducted November 2016 to early-February 2017).
8 pharma companies are included in this 2016 multiple-sclerosis therapy-area analysis:
- Merck KGaA
How pharma is assessed for corporate reputation
- How the pharma industry’s corporate reputation compares with that of other healthcare industries.
- How the pharma industry’s corporate reputation has changed over the past five years.
- How good or bad the pharma industry is at various activities of relevance to patients and patient groups.
7 indicators for the corporate reputation of individual pharma companies:
- Patient centricity.
- Information for patients.
- Patient safety.
- Usefulness of products.
- Patient-group relationships.
“Some drugs have increased in pricing. I think it is ‘gouging’ the consumer who needs medication.”
—Local MS patient group, USA
“Companies have stopped working effectively with the medical profession and the patient community.”
[Russian Multiple Sclerosis Society (RuMSS)], Russia
[Regarding the corporate reputation of healthcare sectors] “They always lack drugs, or they give us different drugs, according to what is available in the pharmacies. But drugs are very scarce.”
—Asociación de Esclerosis Múltiple Jalisco A.C., Mexico
- Patient groups with an interest in multiple sclerosis are marginally more positive about pharma than patient groups from other therapy areas. 41% of multiple-sclerosis patient groups thought that the pharma industry had an "Excellent" or "Good" corporate reputation in 2016, compared with just 37.9% of patient groups across all therapy areas.
- Multiple-sclerosis patient groups ranked pharmacists 1st among 8 healthcare-industry sectors for having a "Excellent" or "Good" corporate reputation in 2016.
- Multiple-sclerosis patient groups ranked pharma 3rd (out of 8) for having a "Excellent" or "Good" corporate reputation in 2016, compared with a ranking of 5th (out of 8) given to it by patient groups from other therapy areas in 2016.
- Multiple-sclerosis patient groups were more positive about the following pharma activities than patient groups from some (but not all) other therapy areas: ability to innovate; supply of high-quality products and high-quality patient information; having a patient-centric strategy; acting with integrity; providing 'beyond-the-pill' services to patients; managing adverse side effects; and being philanthropic.
THE PARTNERSHIPS BETWEEN PHARMA COMPANIES AND PATIENT GROUPS
- 54 patient groups with an interest in multiple sclerosis participated in the 2016 study. They came from Asia, Europe, North America, and Latin America.
- The company with which multiple-sclerosis patient groups were most familiar was Biogen (94% of respondent multiple-sclerosis patient groups were familiar with the company).
INDIVIDUAL COMPANY FINDINGS
- Novartis ranked overall 1st in 2016 for corporate reputation among the 8 pharma companies, when judged by multiple-sclerosis patient groups.
- Novartis also ranked 1st for all seven indicators of corporate reputation among the multiple-sclerosis patient groups.
Multiple-sclerosis patient groups on how pharma can improve its patient relations [summary].
Multiple-sclerosis patient-group relationships with pharma.
Industry-wide findings from multiple-sclerosis patient groups.
Multiple-sclerosis patient groups on improving corporate reputation.
Rankings of the 8 pharma companies among multiple-sclerosis patient groups familiar with them.
Positioning of the 8 pharma companies among partner multiple-sclerosis patient groups.
Individual profiles of the 8 companies, from the perspective of multiple-sclerosis patient groups.
I. Comments from respondent multiple-sclerosis patient groups.
II. Profile of the 54 respondent multiple-sclerosis patient groups.
Charts and Tables
How multiple-sclerosis patient groups rate the corporate reputation of the pharma industry, compared with that of other healthcare sectors, over the past five years; and for specific industry activities, 2016.
Multiple-sclerosis patient groups claiming familiarity, or which worked, with the company, 2016.
Each company's average score for the seven indicators of corporate reputation.
Each company’s overall ranking for corporate reputation among patient groups familiar with the company.
Each company’s overall positioning for corporate reputation among patient groups which partnered with the company.
The company’s best indicators of corporate reputation.
The company’s rankings among patient groups for the indicators of corporate reputation, 2016: multiple sclerosis v. therapy wide; familiar with v. worked with.
Percentage of the patient groups that worked with the company—but which also worked with other companies, 2016.
How the company did at corporate reputation in different countries/regions, compared with its therapy-wide average.
Company's Pharma Corporate Reputation Index (PCRI), multiple sclerosis v. therapy wide 2016.